Abstract:Abstract Abstract 3576 Primary leukemia cells are known to be difficult to culture in vitro. Therefore, mouse xenograft models are commonly used to study human leukemia biology and to develop new therapeutics. Leukemia can be maintained and expanded through serial transplantations. Although many mouse models with different types of leukemia, mouse strains, and inoculation methods, have been used, there are very few studies validating the models. We have established acute lymphoblastic leukemia (ALL) mouse models using primary ALL samples and NOD/SCID/IL2Rg null (NSG) mice. In order to increase engraftment efficiency, we transplanted leukemia cells into healthy adult mice via intra-bone marrow (BM) injection (1 to 100 million cells per mouse to tibia bilaterally). To our knowledge, the model with primary ALL samples in NSG mice via intra-BM injection is novel. A total of 9 samples, 2 T cell ALL and 7 precursor B (preB) ALL, were transplanted into cohorts of 3 to 8 mice each. Of these, 1 T cell ALL and 6 preB ALL samples engrafted and 1 T cell and 1 preB ALL sample failed to engraft. Leukemia engraftment was observed between 10 to 33 weeks after transplantation. In each cohort, each mouse developed leukemia at approximately the same time after leukemia transplantation. Necropsy showed significant hepatosplenomegaly and white BM in all mice, indicating leukemia infiltration. Cells were harvested from BM, spleen and other leukemia-infiltrated organs, and confirmed to be human origin by flow cytometry using anti-HLA-ABC and anti- human CD45 antibodies. Nearly 100% of BM was replaced with human leukemia cells. One T cell and 1 preB ALL sample have been serially transplanted using the same method as the primary transplantation to quaternary and tertiary generations, respectively. We observed that the time to develop leukemia became shorter with each transplantation: 16 weeks for the first transplantation and 10 weeks for the tertiary transplantation in a T cell ALL sample. Some mice transplanted with a preB ALL sample developed chloroma. Interestingly, chloroma development was consistently observed with this sample, which was transferred through serial transplantation although the patient did not develop chloroma. Morphology and immunophenotype were similar to the original leukemia. There were some changes in CD expression patterns; however, immunophenotyping was consistent with the original leukemia. To help understand phenotype progression in transplanted leukemia samples, we are currently comparing the transcriptome profiles of leukemia samples obtained from the patient, primary and quaternary mice for T cell ALL, and primary and tertiary mice for preB ALL samples (preB ALL patient sample not available). Next-generation sequencing (NGS)-based RNA-Sequencing (RNA-Seq) is in progress for this analysis. In addition to obtaining digital expression profiles, and differential gene expression, RNA-Seq analysis will reveal the complete repertoire of splice variants, point mutations, and fusion transcripts in the ALL samples. Complete results of these analyses for our mouse models with both T cell and preB ALL will be presented. Thus, this technique will provide the most detailed transcriptomic analysis and no validation studies have yet been reported on ALL samples sequentially engrafted NSG mice using RNA-Seq. Disclosures: No relevant conflicts of interest to declare.

Abstract 395: Rapid engraftment of human primary acute leukemic cells in NOD/SCID mice by intrasplenic inoculation: a robust human primary leukemia (Hukemia) model for preclinical evaluation of new therapies

Protocol to establish a stable MLL-AF9_AML mouse model.

Abstract 3960: Establishment of humanized mouse models engrafted with luciferase-expressing acute myeloid leukemia cell lines

Successful engraftment of human acute lymphoblastic leukemia cells in NOD/SCID mice via intrasplenic inoculation

Validation of A Human Acute Lymphoblastic Leukemia Mouse Model Using Next Generation Rna Sequencing

3223 – SUPERIORITY OF UNCONDITIONED NRG-W41 MICE EXPRESSING HUMAN IL3/GM-CSF/SCF TO ANALYZE GROWTH AND IN SITU TREATMENT OF PRIMARY HUMAN AML CELLS

Abstract 399: A special childhood T-ALL model of NOD/SCID mice can recapitulate the clinical patient disease

Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice

Use of human AML cells to study graft-versus-leukemia immunity in xenogeneic mouse models of GVHD

Modeling Human Leukemia Immunotherapy in Humanized Mice

Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice

[Establishment of Mouse Model with Humanized Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia].

Construction of a Novel CD34+ Hematopoietic Stem Cell Derived Xenograft Model of Human Hyperleukocytic Acute Myeloid Leukemia

Establishment of a Patient-Derived T-Cell Acute Lymphoblastic Leukemia Xenograft Model in Novel Immunodeficient NCG Mice

[Establishment of Human Acute B-lymphoblastic Leukemia NOD/SCID/IL2 Receptor Γ Chain(null) Neonatal Mouse Xenotransplant Model].

Abstract 118: Development of a novel murine model, NCG-M/hIL15, for enhanced post-HSC transplantation immunoreconstruction

Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease

Abstract 5202: NCG-M Humanized Mice: an Excellent Model for Human Immune Reconstitution of Myeloid Lineages

Establishment of Human Acute Monocytic Leukemia Model in Severe Combined Immunodeficient (SCID) Mice and the Analysis of Pathological Changes

Improved chemotherapy modeling with RAG-based immune deficient mice

Abstract 7397: Application of state transition theory for predicting responses of acute myeloid leukemia to chemotherapy